Heritage Bio Labs · Research use only
Heritage Bio Labs
Front bottle artwork: Heritage Bio Labs RETA / IGF-1 LR3 — 20 mg / 1 mg

Payment Options

  • Cash App logoCash App
  • Apple Pay logoApple Pay
  • PayPal logoPayPal
  • Crypto (USDC) logoCrypto (USDC)

$10 USPS Priority Shipping

Estimated delivery: 2–5 business days. Delivery times may vary.

Orders of $500 or more ship free. Final shipping details at checkout.

← Back to shop
!For Research Use Only

RETA / IGF-1 LR3 — 20 mg / 1 mg

$127.49

This name denotes a proposed combination of retatrutide and long-arginine-3 IGF-1. It pairs multi-receptor metabolic research with IGF-receptor growth signaling; the component literature does not establish performance of the named blend. For research use only; not for human or veterinary use.

Research Use Only. Not for human consumption, diagnostic use, or clinical application. Priced items use order requests; unpriced catalog listings are inquiry-only.

Full description

Educational research context. The cited studies and supplier descriptions do not verify the identity, testing, or effects of this Heritage product.

RETA is shorthand for retatrutide, a peptide that activates GIP, GLP-1, and glucagon receptors. IGF-1 LR3 is an engineered insulin-like growth factor analogue with an extended amino terminus and a substitution at position three. Its reduced interaction with IGF-binding proteins makes it useful for studying growth-factor responses in cell culture. The combination name therefore joins metabolic-hormone signaling with an independent growth-factor pathway rather than identifying a single new peptide.

Retatrutide trials report body-weight reduction in defined clinical populations. GroPep describes LR3 IGF-I as a reagent developed to support mammalian-cell survival and proliferation. Juxtaposing these functions suggests a research concept involving weight regulation alongside anabolic or cell-growth signaling; that is an interpretation of the component pairing, not a verified statement from an identified blend listing. No matching Umbrella combination was found in the supplied catalog capture. Neither the retatrutide trial nor the LR3 reagent documentation evaluates this two-component product, its interaction, or muscle preservation during weight loss. The available description is therefore component-based rather than evidence of a clinically validated combination.

Sources

  1. Retatrutide phase 2 obesity trialLiterature record (study type requires review)
  2. GroPep — Human LR3 IGF-I specificationsExternal reference (requires review)
  3. Umbrella Labs — peptide-blend catalogSupplier listing (not independent scientific evidence)

For research use only. Not for human or veterinary use; not medical advice.

Questions? Chat with a real human.